Drugs / OlyCAR-019
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05932173 | Jul 2023 → Jun 2024 | B-cell neoplasm, lymphoid leukemia | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OlyCAR-019 | “The OlyCAR-019 cells will be infused by vein.” NCT05932173 ↗ |
| Modality | Cell therapy | “CAR-T cells” NCT05932173 ↗ |
| Route | Intravenous | “infused by vein” NCT05932173 ↗ |
| Target | CD19 | “Autologous T cells modified with anti-CD19 ScFv expression” NCT05932173 ↗ |